Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Using the Quantamatrix Multiplexed Assay Platform System
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The increasing prevalence of drug-resistant tuberculosis (TB) infection represents a global public health emergency. We evaluated the usefulness of a newly developed multiplexed, bead-based bioassay (Quantamatrix Multiplexed Assay Platform [QMAP], QuantaMatrix, Seoul, Korea) to rapidly identify the Mycobacterium tuberculosis complex (MTBC) and detect rifampicin (RIF) and isoniazid (INH) resistance-associated mutations. Methods: A total of 200 clinical isolates from respiratory samples were used. Phenotypic anti-TB drug susceptibility testing (DST) results were compared with those of the QMAP system, reverse blot hybridization (REBA) MTB-MDR assay, and gene sequencing analysis. Results: Compared with the phenotypic DST results, the sensitivity and specificity of the QMAP system were 96.4% (106/110; 95% confidence interval [CI] 0.9072–0.9888) and 80.0% (72/90; 95% CI 0.7052–0.8705), respectively, for RIF resistance and 75.0% (108/144; 95% CI 0.6731–0.8139) and 96.4% (54/56; 95% CI 0.8718–0.9972), respectively, for INH resistance. The agreement rates between the QMAP system and REBA MTB-MDR assay for RIF and INH resistance detection were 97.6% (121/124; 95% CI 0.9282–0.9949) and 99.1% (109/110; 95% CI 0.9453–1.0000), respectively. Comparison between the QMAP system and gene sequencing analysis showed an overall agreement of 100% for RIF resistance (110/110; 95% CI 0.9711–1.0000) and INH resistance (124/124; 95% CI 0.9743–1.0000). Conclusions: The QMAP system may serve as a useful screening method for identifying and accurately discriminating MTBC from non-tuberculous mycobacteria, as well as determining RIF- and INH-resistant MTB strains.
Abstract
Background: The increasing prevalence of drug-resistant tuberculosis (TB) infection represents a global public health emergency. We evaluated the usefulness of a newly developed multiplexed, bead-based bioassay (Quantamatrix Multiplexed Assay Platform [QMAP], QuantaMatrix, Seoul, Korea) to rapidly identify the Mycobacterium tuberculosis complex (MTBC) and detect rifampicin (RIF) and isoniazid (INH) resistance-associated mutations. Methods: A total of 200 clinical isolates from respiratory samples were used. Phenotypic anti-TB drug susceptibility testing (DST) results were compared with those of the QMAP system, reverse blot hybridization (REBA) MTB-MDR assay, and gene sequencing analysis. Results: Compared with the phenotypic DST results, the sensitivity and specificity of the QMAP system were 96.4% (106/110; 95% confidence interval [CI] 0.9072–0.9888) and 80.0% (72/90; 95% CI 0.7052–0.8705), respectively, for RIF resistance and 75.0% (108/144; 95% CI 0.6731–0.8139) and 96.4% (54/56; 95% CI 0.8718–0.9972), respectively, for INH resistance. The agreement rates between the QMAP system and REBA MTB-MDR assay for RIF and INH resistance detection were 97.6% (121/124; 95% CI 0.9282–0.9949) and 99.1% (109/110; 95% CI 0.9453–1.0000), respectively. Comparison between the QMAP system and gene sequencing analysis showed an overall agreement of 100% for RIF resistance (110/110; 95% CI 0.9711–1.0000) and INH resistance (124/124; 95% CI 0.9743–1.0000). Conclusions: The QMAP system may serve as a useful screening method for identifying and accurately discriminating MTBC from non-tuberculous mycobacteria, as well as determining RIF- and INH-resistant MTB strains.
참고문헌 (24)
- Zaman K, "Tuberculosis: a global health problem", J Health Popul Nutr, 28, pp.111~113 (2010)
- 배은신, "항산균 배양에서 BACTEC Mycobacteria Growth Indicator Tube 960 System과 Ogawa 배지 병용의 평가", Annals of Laboratory Medicine, 28(4), pp.299~306 (2008), 대한진단검사의학회
- Parsons LM, "Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities", Clin Microbiol Rev, 24, pp.314~350 (2011)
- Rageade F, "Performance of solid and liquid culture media for the detection of Mycobacterium tuberculosis in clinical materials: meta-analysis of recent studies", Eur J Clin Microbiol Infect Dis, 33, pp.867~870 (2014)
- Blakemore R, "Evaluation of the analytical performance of the Xpert MTB", RIF assay, 2010, pp.48, 2495~2501
- Skenders GK, "Implementation of the INNO-LiPA Rif. TB® line-probe assay in rapid detection of multidrug-resistant tuberculosis in Latvia", Int J Tuberc Lung Dis, 15, pp.1546~1552 (2011)
- Teo J, "Comparison of two nucleic acid amplification assays, the Xpert MTB", RIF assay and the amplified Mycobacterium Tuberculosis Direct assay, for detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens, 2011, pp.49, 3659~3662
- Singhal R, "Detection of multi-drug resistance & characterization of mutations in tuberculosis isolates from North-Eastern States of India using GenoType MTBDRplus assay", Indian J Med Res, 140, pp.501~506 (2014)
- Sharma SK, "Evaluating the diagnostic accuracy of Xpert MTB", RIF assay in pulmonary tuberculosis, 2015, pp.10, e0141011~
- Rahman A, "Comparison of Xpert MTB", RIF assay and GenoType MTBDRplus DNA probes for detection of mutations associated with rifampicin resistance in Mycobacterium tuberculosis, 2016, pp.11, e0152694~
- Seifert M, "A performance evaluation of MTBDRplus version 2 for the diagnosis of multidrug-resistant tuberculosis", Int J Tuberc Lung Dis, 20, pp.631~637 (2016)
- Kim LN, "Shape-encoded silica microparticles for multiplexed bioassays", Chem Commun, 51, pp.12130~12133 (2015)
- Wang HY, "Performance of the Quantamatrix Multiplexed Assay Platform system for the differentiation and identification of Mycobacterium species", J Med Microbiol, 66, pp.777~787 (2017)
- Wang HY, "Quantamatrix Multiplexed Assay Platform system for direct detection of bacteria and antibiotic resistance determinants in positive blood culture bottles", Clin Microbiol Infect, 23, pp.333.e1~333.e7 (2017)
- Abbadi SH, "Molecular identification of mutations associated with anti-tuberculosis drug resistance among strains of Mycobacterium tuberculosis", Int J Infect Dis, 13, pp.673~678 (2009)
- Tessema B, "Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia", BMC Infect Dis, 12, pp.37~ (2012)
- Luo T, "Selection of mutations to detect multidrug-resistant Mycobacterium tuberculosis strains in Shanghai, China", Antimicrob Agents Chemother, 54, pp.1075~1081 (2010)
- Slayden RA, "The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis", Microbes Infect, 2, pp.659~669 (2000)
- Jin J, "Evaluation of the GenoType® MTBDRplus assay and identification of a rare mutation for improving MDR-TB detection", Int J Tuberc Lung Dis, 16, pp.521~526 (2012)
- Yadav RN, "Comparative evaluation of GenoType MTBDRplus line probe assay with solid culture method in early diagnosis of multidrug resistant tuberculosis (MDR-TB) at a tertiary care centre in India", PLoS One, 5, pp.e72036~ (2013)
- Causse M, "New Anyplex™ II MTB", MDR, Int J Tuberc Lung Dis, pp.2015, 19[DOI]
- Hristea A, "Detection of Mycobacterium tuberculosis resistance mutations to rifampin and isoniazid by real-time PCR", Indian J Med Microbiol, 28, pp.211~216 (2010)
- Chien JY, "Performance assessment of the BluePoint MycoID plus kit for identification of Mycobacterium tuberculosis, including rifampin- and isoniazid-resistant isolates, and nontuberculous mycobacteria", PLoS One, 10, pp.e0125016~ (2015)
- Bai Y, "GenoType MTBDRplus Assay for rapid detection of multidrug resistance in Mycobacterium tuberculosis: a meta-analysis", PLoS One, 11, pp.e0150321~ (2016)